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Summary: Insulin-like growth factors are growth-promoting peptides structurally related to insulin which possess
autocrine and paracrine activities. IGF-I is mainly synthesized in hepatocytes, but little is known about its paracrine
action on hepatocyte-adjacent perisinusoidal hepatic stellate cells, the principal matrix producing precursor cell
type in the liver. IGF-I might stimulate proliferation and phenotypical transformation of hepatic stellate cells into
myofibroblasts, the cell type responsible for the excessive production of connective tissue elements during fibrogen-
esis. In this study we investigated the expression and function of the IGF-I receptor during transformation of
isolated and cultured hepatic stellate cells. The respective stages of transformation of hepatic stellate cells were
defined by determination of cellular smooth muscle iso-a-actin and retinyl-palmitate content, respectively. IGF-I
receptor protein decreased stage-dependently down to 0.5 at the 4th day and about 0.17 at the 8th day. The number
of IGF-I receptors was determined to be initially 1.3 X 105/cell. Their quantity decreased to 0.8 Χ 105 sites/cell
(4th day) down to 0.5 Χ 105 sites/cell at the 7th day and remained constant thereafter at 0.7 X 10s sites/cell. Dissoci-
ation constants (KD) for IGF-I range from 0.32—0.57 nmol/1 showing constantly high receptor affinity. Northern
blot analyses revealed distinct upregulation of IGF-I receptor mRNA level during culture. It is concluded that
hepatocyte-generated IGF-I and/or IGF-I binding proteins are candidate mediators of hepatic stellate cell activation
during the initial period of transformation to myofibroblasts. After completion of transformation the cell becomes
relatively refractory to the action of IGF-I as judged from receptor density.
1. Introduction
The perisinusoidal hepatic stellate cell (HSC, also ter-
mined vitamin A storing cell, fat storing cell, or Ito cell)
(1,2) has attracted much interest because of its prominent
pathophysiological role as the precursor cell type respon-
sible for liver fibrpgenesis (3—5). Adjacent to endothelial
cells and closely connected to hepatocytes by microvilli
contact (6), inflammatory stimuli activate the resting reti-
noid storing hepatic stellate cell to proliferate, to trans-
form phenotypically into myofibroblasts (MFB), and to
express and synthesize a wide variety of extracellular ma-
trix components which accumulate during the develop-
ment of fibrosis (7-10). Activation of hepatic stellate
cells is generally regarded as the crucial step in the mo-
lecular and cellular pathogenesis of fibrogenesis (11, 12).
The in situ transformation of hepatic stellate cells via
transitional cells into myofibroblasts (13, 14) is charac-
terized by ultrastructural changes and loss of specific
cell contents (2). The concentration of retinyl-palmitate
is reduced and the expression of smooth muscle iso-a-
actin is strongly upregulated (15—17). Similar to in situ
activation of hepatic stellate cells in areas of necro-in-
flammation, a spontaneous transformation process is ob-
served in isolated hepatic stellate cells grown on plain
plastic support (18, 19).
The growth promoting, insulin related peptide, insulin-
like growth factor (IGF)-I is a candidate paracrine medi-
ator of stimulation of hepatic stellate cell proliferation
and transformation (20). IGF-I2) is produced in signifi-
cant quantities by hepatocytes (21—26) and is function-
ally modulated by co-synthesized IGF binding proteins
(27—29); thus, the hepatic stellate cell is constantly ex-
posed to a relatively high concentration of IGF-I in the
immediate microenvironment. It was suspected that the
action of IGF-I on hepatic stellate cells might depend
strongly on the quantity and quality of the IGF-I recep-
tor, a tyrosine kinase receptor related to the insulin re-
ceptor (30, 31). In the present study, we established
quantitative and qualitative measures of IGF-I receptor
sites as a function of the respective stage of hepatic stel-
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late cell transformation to get a more detailed insight
into the functional mechanism by which IGF might me-
diate hepatic stellate cell activation. It was found that
receptor affinity and quantity are differently regulated
during hepatic stellate cell transformation, which offers
an additional regulation of hepatic stellate cell activation
at the level of IGF-I receptor expression.
2. Materials and Methods
2.1. Chemicals and reagents
Enzymes for hepatic stellate cell isolation, Dulbecco's modified
Eagle medium (DMEM), fetal calf serum (PCS), smooth muscle
iso-a-actin antibodies, and human recombinant insulin-like growth
factors-1/Il (hIGF-I/hlGF-11) were purchased from Boehringer
Mannheim GmbH, Mannheim, Germany. Anti-hIGF-I rabbit antise-
rum (UB3-189) was a gift from Drs. Lows Underwood and Judson
J. van Vfyk* Division of Pediatric Endocrinology, University of
North Carolina, Chapel Hill, USA; rat cross-reactive mouse mo-
noclonal human IGF-I receptor ß-subunit antibody was a gift from
Dr. Ken Siddle, Dept. of Clinical Biochemistry, University of Cam-
bridge, UK. Rat IGF-I receptor cDNA was generously provided by
Dr. Derek LeRoith, NIH; Bethesda, USA. Fluorescein isothiocyana-
te(FITC)-conjugated anti-mouse IgG was from Dakopatts, Ham-
burg, Germany. [3-I25I]iodotyrosyl insulin-like growth factor-I
(specific activity 74 TBq/mmol) and the enhanced chemolumines-
cence Western blotting detection kit were obtained from Amersham
Buchler, Braunschweig, Germany. X-OMAT AR autoradiography
film was from Kodak.
2.2. Isolat ion and cul ture of hepat ic stellate cells
The isolation and characterization of hepatic stellate cells was per-
formed as described previously (32, 33). The purity of hepatic stel-
late cells was > 0.98 after the first medium change. The plating
efficiency reached 0.52—0.61, and the viability of cells, assessed
by trypan blue exclusion, was found to be > 0.95 after 24 h and
after 6 d of culture, respectively. For receptor binding studies, he-
patic stellate cells were seeded with a density of 1.5 X 104/cm2
in 24-well culture plates (2 cm2/well; Greiner GmbH, Nurtingen,
Germany) or for Northern and Western blotting experiments in cul-
ture flasks (75 cm2) and grown as monolayers in DMEM contain-
ing 0.1 fetal calf serum. Special care was taken to exclude non-
specific radioligand binding effects to culture well plastic surfaces
and/or surface adherent IGF binding proteins derived from fetal
calf serum supplement (34), by presaturating with excess RIA
grade bovine serum albumin (0.01, 3 h, 37 °C) before use. Medium
changes were carried out at the 1 st, 4th and 8th day after seeding.
2.3. Determination of cell p ro l i fe ra t ion
The actual cell number at each stage of hepatic stellate cell trans-
formation was indirectly determined by fluorometric measurement
of the DNA content of two culture wells (4 cm2) in triplicate, using
calf thymus DNA as a standard (35). DNA quantities were then
correlated to phase contrast microscopic cell numerations.
buffered saline and then reacted with fluorescein isothiocyanate-con-
jugated anti-mouse IgG (1 : 50 in phosphate buffered saline, 0.01 bo-
vine serum albumin, 1 h, 22 °C). After two final washes with distilled
water, the cell layers of four culture wells (8 cm2, triple determination)
were scraped off, suspended in distilled water and pooled. Subsequent
fluorometric measurement was carried out in an SFM-25 spectrofluor-
ometer (Kontron Analytical, Eching, Germany) at an excitation wave-
length of 470 nm, analysed at 520 nm emission wavelength. Immuno-
fluorescence intensity was expressed as the complementary percen-
tage value of the photomultiplier high voltage requirement to produce
maximum sample fluorescence, compared to the absolute maximum
value detected at the llth culture day. To confirm complete trans-
formation of hepatic stellate cells, another reference value was taken
at the 14th culture day.
2.5. Determination of cellular retinyl-palmitate content
All preparations were performed under light protected conditions.
For triplicate determination, cell layers of two culture wells (4 cm2)
were washed twice with phosphate buffered saline, scraped off in
0.5 ml phosphate buffered saline suspension volume, and stored at
—30 °C until use. Retinoids were extracted with /z-hexane after com-
plete cell disruption by repeated freezing and thawing and protein
precipitation with 0.5 (by vol.) ethanol. After phase separation (cen-
trifugation at 600 g, 5 min, 4 °C), aliquots of the /z-hexane phase
were taken for HPLC analysis (RP-18 column Nucleosil 100-5-Si,
Latek, Heidelberg, Germany; mobile phase n-hexane iso-propanol,
94 + 6 (by vol.); flow rate 1.5 ml/min; UV-detection at 330 nm;
22 °C). The retinyl-palmitate concentration was calculated using the
"External Standard Quantification" method of peak area integration
of the recording integrator (Waters, Eschborn, Germany).
2.6. Isolat ion of total RNA and Northern blot
hybridization analysis of IGF-I receptor mRNA
Total cellular RNA was extracted from freshly isolated, eight day
old cultured hepatic stellate cells according to Chomczynski &
Saachi (36). For Northern blot analysis, total RNA was separated
using a denaturating 0.012 agarose, 0.06 formaldehyde gel fol-
lowed by the blotting procedure described elsewhere (37).
2.7. Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and
Western blot analysis
Cultures of differently transformed hepatic stellate cells (days 2,
4, 8) were extracted on ice, using 0.02 sodium dodecyl sulphate
electrophoresis sample buffer in the presence of protease inhibitors.
Aliquots (5 g/1 protein) were subjected to sodium dodecyl sulphate-
PAGE (0.08 polyacrylamide) under non-reducing conditions using
the discontinuous buffer system of Laemmli (38). Prestained mo-
lecular weight markers were used. For immunoblotting, the electro-
phoresed samples were transformed onto nitrocellulose by fast
semi-dry electroblotting (200 mA/8-20V, 30-45 min) using a
synthetic carbon electrode blotting device (HLI, Landsberg, Ger-
many) and incubated with specific primary antibodies against IGF-
I receptor (final dilution 1 : 500). Bound antibodies were detected
using the Amersham enhanced chemoluminescence Western detec-
tion kit.
2.4. Est imat ion of expression of ce l lu la r smooth muscle
iso-a-actin by indirect immunofluorescence
Cell layers were washed twice with ice-cold phosphate buffered saline
(PBS), pH 7.4, then fixed using 0.05 (by vol.) acetic acid in ethanol.
Three washing steps with phosphate buffered saline was followed by
blocking of unspecific binding with 1 : 2 diluted fetal calf serum (30
min, 22 °C). Cells were then reacted with smooth muscle anti-iso-a-
actin (1 :50) antibody in phosphate buffered saline containing 0.01
bovine serum albumin for 1 hour at ambient temperature on a rotating
platform. The cells were washed again three times with phosphate
2.8. Performance of the radioreceptor assay (RRA)
and validation of rat hepatic stellate cell receptor
specifici ty for hIGF-I by displacement and
immunoneutral izat ion studies
To perform IGF-I displacement and IGF-I immunoneutralization
experiments, we used hepatic stellate cells grown for 3 to 8 days
in 24-well multidishes in the presence of 0.1 fetal calf serum sup-
plemented medium. After aspiration of the culture medium, mono-
layers were washed twice with binding buffer (128 mmol/l NaCl,
5 mmol/l KC1, 1.2 mmol/l CaCl2, 1.2 mmol/l MgSO4, 50 mmoVl
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HEPES, pH 7.4, and 0.005 bovine serum albumin RIA grade) and
incubated for 45 minutes at 37 °C in binding buffer to allow com-
plete incorporation of cell associated IGF. After equilibration for
about 15 min at ambient temperature (20-22 °C), the assay vol-
ume was adjusted to 500 μΐ/well with binding buffer, including
185 Bq of [125I]IGF-I. To verify IGF-I receptor specificity, IGF-I
(0.25, 1, 2.5, 5, 10, 25, 100 ng/we!l), 1GF-I1 (1, 5, 50, 500 ng/well)
and insulin (10, 50, 500, 5000 ng/well) were added as competing
peptides. Ligand specificity was tested by immunoneutralization of
[125I]IGF-I in the presence of different dilutions of anti-hIGF-I rab-
bit antiserum UB3-189. To avoid non-specific ligand adhesion to
plastic surfaces of culture wells or attached IGF binding proteins
derived from fetal calf serum, measurements of [I25I]IGF-I dis-
placement were carried out in plain culture dishes not presaturated
or presaturated for 3 h at 37 °C with 10 g/l RIA grade bovine serum
albumin both in the absence and presence of 0.1 (by vol.) fetal calf
serum and/or 5 ng/well IGF-I.
Incubations were performed for 3 hours at 20 °C on a rotating
platform and terminated by aspirating the supernatant, followed by
immediate washings with ice cold binding buffer. Specifically
bound radioactivity was then liberated from cell surfaces with 0.01
Triton X-100 in phosphate buffered saline for 15 minutes on a
rotating platform (~ 180 min""1, 22 °C). Radioactivity was mea-
sured in a Berthold gamma-counter (EG & G Berthold GmbH, Bad
Wildbad, Germany).
2.9. Quant i f icat ion of number and af f in i ty of IGF-I re-
ceptors with the radioreceptor assay (RRA)
At the 2nd, 4th, 7th, 9th and 1 Ith day after seeding, hepatic stellate
cell monolayers in 24-welI culture plates were processed as de-
scribed in the previous section. Scatchard analyses and displace-
ment calculation data, to ascertain dissociation constants (KD) and
binding capacity values, were derived from IGF-I binding curves,
which were computed with the IBM-PC version of the LIGAND
(Scafit) program (courtesy of Dr. R J. Munson, NIH, Bethesda,
MD, USA) (39).
3. Results
Culture of rat liver hepatic stellate cells seeded with low
density leads to continuous cell proliferation and com-
pletely transformed myofibroblasts (fig. la-c). The ini-
tially homogenously spread hepatic stellate cells started to
change their spherical cell shape with perinuclear lipid
droplets at the 3rd day after seeding by flattening and irreg-
ular increase in diameter, indicating the beginning of the
transformation process (fig. la). During the following
days, the cells developed characteristic cellular extensions
along with actin fibers. In parallel, the number and size of
fat droplets decreased (fig. Ib). Between the 7th and 9th
culture days, hepatic stellate cells reached subconfluency
and nearly all of them had a completely transformed myo-
fibroblastic phenotype with no fat droplets visible (fig. Ic).
These morphological changes were accompanied by two
measurable modifications used frequently as indicators
of hepatic stellate cell transformation. Expression of
smooth muscle iso-a-actin was monitored using the
newly described fluorescein isothiocyanate-immunoflu-
orescence assay, and cellular retinyl-palmitate content
was determined by reverse phase HPLC (fig. 2). It could
be shown that the different stages of cell transformation
exhibit an antiparallel course of increasing actin expres-
Fig. 1 Phase contrast micrographs of rat hepatic stellate cells
(HSC) at
a) an early (2nd day),
b) an intermediate (5th day), and
c) a late (9th day) stage of transformation into myofibroblasts (bar
represents 30 μιη).
sion and decreasing amounts of retinyl-palmitate. Maxi-
mum changes in non-confluent hepatic stellate cells oc-
cured up to the 7th day after seeding, documented by a
0.77 increase of actin antibody related fluorescein iso-
thiocyanate fluorescence, and a 0.52 decrease of retinyl-
palmitate content. The values ascribed to completely
transformed cells were reached 4 days later, displaying
finally 0.92 actin related fluorescence and an overall loss
of 0.76 of retinyl-palmitate (fig. 2b). Interestingly, myo-
fibroblasts still contain detectable amounts of retinyl-
palmitate, i.e. 3 μg/106 cells, at the 14th day, measured
as described in continuous cultures from the quoted ex-
periments.
The determination of IGF-I receptor protein expression
in transforming hepatic stellate cells by Western blotting
experiments revealed that type I IGF receptor (IGF-I-R) is
present in all stages of transformation. The amount of IGF-
I receptor protein decreased from a maximum value at die
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Fig. 2 a) Cell proliferation of spontaneously transforming hepatic
stellate cells (HSC) from rat liver grown as non-confluent mono-
layers on uncoated plastic.
b) Concentration of cellular retinyl-palmitate content (—) and ex-
pression of a-actin \measured by antibody related fluorescein iso-
thiocyanate fluorescence (—) in hepatic stellate cells during in vi-
tro transformation.
2nd culture day down to about 0.5 at the 4th day and
finally reached about 0.17 at the 8th day (fig. 3).
To determine the specificity of IGF-I binding sites on
rat hepatic stellate cells and to exclude non-specific IGF
binding to plastic surfaces or to attached IGF binding
proteins derived from fetal calf serum, exhaustive con-
trol experiments were carried out. As shown in figure 4,
presaturation of plastic culture wells with bovine serum
albumin generally resulted in a reduction of non-specific
binding of the radiolabelled peptide hormone. In gene-
ral, presaturation with bovine serum albumin decreased
202 —*>
133 —+·
ß-subunit ·
71
42
Fig. 3 Western blot analysis of cell extracts from 2, 4 and 8 day
old cultured hepatic stellate cells (HSC) processed by sodium do-
decyl sulphate-PAGE (0.08) under non-reducing conditions, blot·?
ted and reacted with IGF-I receptor antibody directed against the
ß-subunit. Arrows indicate positions of molecular weight markers.
non-specific [125I]IGF-I binding by 0.5 to 0.6 (fig. 4).
In contrast, pretreatment of unsätürated wells with 0. 1
fetal calf serum enhanced non-specific binding of radio-
labelled IGF-I by 0.1, probably due to its content of IGF
binding proteins. Again, this effect could be reduced by
presaturation with bovine serum albumin (fig. 4).
Regular, dose-dependent displacement was achieved
when adding increasing concentrations of unlabelled IGF-
I (0.25 to 100 ng/well) to 7 to 8 day old cultures of he-
patic stellate cells, leading to 0.21 to 0.98 reduction of
bound [125I]IGF-I (fig. 4, 5). Immunoneutralization of
[125I]IGF-I by 1 : 5000 to 1 : 200 dilutions of anti-IGF-I
rabbit antiserum displayed specificity of the respective
| HSC monolayer wells
Insulln-JIke growth factor-) [ng/well]
Fig. 4 Determination of binding of [125I]IGF-I (185 Bq/well) to
culture wells and the hepatic stellate cells (HSC) monolayer
surface, respectively, with (solid bars) and without (open bars) pre-
saturation (bovine serum albumin RIA grade, 10 g/1). In blank
experiments (right) fetal calf serum was added at 50 mg/well and
IGF-I at 5 ng/well, respectively. Values are means of triplicate
determinations.
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Fig. 5 IGF-I radioreceptor specificity assay carried out on early
(3rd day) and transformed (8th day) rat liver hepatic stellate cells
(HSC) displaying competitive displacement of [125I]JGF-I (185 Bq/
well) by different concentrations (ng/well) of various ligands: IGF-
I (open bars), IGF-II (hatched bars), and insulin (solid bars). Values
are means of triplicate determinations of one representative experi-
ment.
ligand (data not shown). This was documented by a dose-
dependent decrease of ligand binding of 0.49 to 0.93.
During all stages of hepatic stellate cell transformation,
[125I]IGF-I binding was inhibited in a dose-dependent
manner by increasing concentrations of IGF-I, as shown
in typical displacement curves (fig. 5). Comparable
competitive action of the related peptides IGF-II (20-
fold concentration) and insulin (200-fold concentration)
characterized IGF-I receptor specificity in early (3rd
day) and late (8th day) hepatic stellate cells (fig. 5, 6).
Scatchard analyses from IGF-I binding data of primary
and transformed hepatic stellate cells displayed abso-
lutely linear and parallel plots (fig. 7), supporting the
notion that [125I]IGF-I is bound to a single class of bind-
ing sites. The quality of the IGF-I receptor, expressed
by ΚΏ values, ranged from 0.32 to 0.57 nmol/1 IGF-I,
indicating constantly high ligand affinity, whereas the
quantity decreased from 1.3 X 105 sites/cell (0.2 amol/
cell) at the 2nd culture day to 0.8 Χ 105 sites/cell (0.13
amol/cell) at the 4th day. Further reduction to less than
0.5 of the initial value at the 7th day (0.5 X 10s sites/
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Fig. 6 Competitive displacement curves for IGF-I (Δ) binding to
its corresponding receptor and for IGF-II binding to the IGF-I re-
ceptor (φ) in
a) early (2nd day),
b) transforming (7th day) and
c) transformed (llth day) hepatic stellate cells (HSC).
Values are means of triplicate determinations of at least two sim-
ilar experiments.
cell, 0.08 amol/cell) and then stable numbers of 0.7
Χ 105 sites/cell (0.11 amol/cell) at the 9th and llth day
were measured (tab. 1). Though detectable amounts of
the IGF-I receptor were found to be present in myofi-
broblasts, IGF-I receptor activity seems to be predomi-
nantly present in the early phase of hepatic stellate cell
transformation.
Tab. 1 Specific binding affinities and total number of IGF-I bind-
ing sites in hepatic stellate cells during transformation to myo-
fibroblasts assessed by radioreceptor assay. Data represent tripli-
cate determinations of at least two similar experiments.
Culture time
Μ
2
4
7
9
11
Affinity constant
(#A)
[I/nmol]
1.76
2.42
3.12
2.75
2.32
Dissociation constant
(*D)
[nmol/1]
0.57 ± 0.20
0.41 ±0.18
0.32 ± 0.06
0.36 ± 0.05
0.43 ± 0.05
Binding capacity
[pmol/1]
6.77
7.23
5.68
8.43
10.80
Binding sites
[amol/cell]
0.21
0.13
0.08
0.11
0.11
[105/cell]
1.26 ±0.40
0.79 ± 0.30
0.47 ± 0.07
0.66 ± 0.08
0.68 ± 0.06
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Fig. 7 Scatchard analysis of IGF-1 binding calculated for one
binding site. Hepatic stellate cells at the 2nd day (Δ) and llth day
(o) were studied. Values are means of triplicate determinations of
at least two experiments.
IGF-l-receptor
0 8
Time [d]
Fig. 8 Northern blot analysis of total cellular RNA of
a) freshly isolated (0) and eight day old cultures of (8) hepatic
stellate cells (HSC) probed for IGF-I receptor mRNA and
b) for S6 raRNA used as internal standard.
In Northern blotting experiments, the steady state level
of IGF-I receptor mRNA was very low in freshly iso-
lated hepatic stellate cells (visible only after long expo-
sure), but increased strongly in cells after 8 days in cul-
ture (fig. 8).
4. Discussion
Close anatomical connection of hepatic stellate cells
with hepatocytes (6, 40), in combination with hepatic
stellate cells stimulating activity present in hepatocyte-
conditioned media (41), strongly suggests participation
of parenchymal liver cells in hepatic stellate cell activa-
tion in necro-inflammatory areas of the liver (12, 42).
Our recent investigations show that IGF-I, which origi-
nates from cultured hepatocytes (21-26, 43), might be
a candidate mediator of hepatic stellate cell activation
(20). Additionally, its stimulatory potential can be en-
hanced by specific IGF binding proteins (27, 28),
secreted at least partially by hepatocytes (20). It was
shown that hepatic stellate cells produce IGF as well as
IGF binding proteins (44, 45), suggesting the potential
of an additional, autocrine pathway in addition to hepa-
tocyte-derived stimuli. Although IGF-I should be pre-
sent in significant concentrations in the microenviron-
ment of hepatic stellate cells, nothing is known about
the cognate receptor of hepatic stellate cells, which is
crucial for the action of this cytokine (30). The present
study was based on the hypothesis that the expression
and function of IGF-I receptor might be subject to vari-
ation during hepatic stellate cell transformation as is the
case for other cytokine receptors on hepatic stellate
cells, e. g. for PDGF3)-receptors (46). By regulation of
the receptor level and affinity, IGF-I originating either
from autocrine or paracrine loops might obtain stage-
dependent activity on hepatic stellate cells.
To obtain full transformation of primary cells within one
batch of culture, low seeding densities were chosen. Cell
proliferation kinetics assured that no cellular contact in-
hibition took place until cells reached subconfluency at
the 9th to llth day. Transformational stages were well
documented by determining retinyl palmitate content
and smooth muscle iso-c^actin expression using a newly
developed immunofluorescence semiquantification
method. A strong rise of actin antibody related fluores-
cein isothiocyanate fluorescence was measured at the
end of the culture period, combined with a decrease of
cellular retinyl palmitate content to 5 μg/106 cells;
freshly seeded hepatic stellate cells contained about 20—
30 pg (fig. 9).
Reliability of the radioreceptor assay using radioiodin-
ated IGF (34) was achieved by presaturation of culture
wells with RIA-grade bovine serum albumin. Non-spe-
cific binding of the radioactive ligand to charged plastic
surfaces and/or adherent IGF binding proteins originat-
ing from fetal calf serum supplement (47) was thus
greatly reduced. Ligand displacement and immunoneut-
ralization experiments revealed specific IGF-I receptor
binding sites present on hepatic stellate cells during all
stages of transformation. This was supported by North-
ern blot analyses and in agreement with the findings of
Zindy and co-workers (45), who documented expression
of mRNAs for IGF-I-, IGF-II-, and insulin receptors in
secondary cultures of hepatic stellate cells, i.e. myofi-
broblasts. Moreover, we could show that freshly isolated
hepatic stellate cells possess only small amounts of IGF-
I receptor mRNA, and that mRNA upregulation obvi-
ously takes place early in culture as a distinct response
to injurious stimuli in vitro. With special regard to func-
tional characteristics, we have shown that expression of
3) PDGF = platelet derived growth factor
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Fig. 9 Schematic presentation of the quantitative changes of the
characteristics of IGF-I receptor in relation to major conditions of
cellular transformation of hepatic stellate cells (HSC) into myofi-
broblasts (MFB). The time-dependency is given on the y-axis.
IGF-I receptor is differently regulated over time. IGF-I
is bound to a single class of binding sites during the
whole course of transformation, which possess high and
rather constant receptor affinity, as documented by
dissociation constant values within a narrow range from
0.32 to 0.57 nmol/1 IGF-I. Comparable results for IGF-I
receptor affinities are quoted for 3T3-L1 adipocytes with
a dissociation constant of 1.1 nmol/1 (48) and human
colon cancer cells with dissociation constants of 1.ΟΤ-
Ι.45 nmol/1 and tumor membranes with dissociation
constants of 0.62-1.13 nmol/1 IGF-I (49). Specificity
was established by competitive displacement of bound
radioiodinated IGF-I by cold IGF-II and insulin which
resulted in affinity constants to the IGF-I receptor being
ten to a hundred times lower than that for IGF-I as re-
ported by others (50). It is interesting that the specific
cellular binding capacity for IGF-I decreased continu-
ously during ongoing transformation, down to 0.7 X 10s
IGF-I receptor/cell at the 9th culture day, representing
approximately 0.5 of the initial IGF-I receptor density
of 1.3 Χ 105 IGF-I receptor/cell. The latter number is
comparable to 1.50-1.95 X 10s IGF-I binding sites per
colon cancer cell (49). In agreement with the functional
results, IGF-I receptor protein is comparably decreased
as judged from Western blots. The decreasing number
of IGF-I binding sites, in view of the mRNA upregula-
tion for IGF-I receptor during transformation of hepatic
stellate cells, suggests translational/posttranslational
modulation of cell surface receptor expression in addi-
tion to transcriptional regulation.
In conclusion, our findings prove stage-dependent re-
duction of IGF-I receptor quantity, but not of affinity,
during spontaneous transformation of hepatic stellate
cells in culture as it is summarized in figure 9. Since
this phenotypic change mimics hepatic stellate cell
transformation in injured liver, it is suggested that at
least early stages of transforming hepatic stellate cells in
rat liver might receive paracrine stimuli via hepatocyte-
derived IGF-I, the activity of which can be modulated
by specific IGF binding proteins. In addition, the par-
acrine IGF stimulation might be supplemented by an au-
tocrine amplification mechanism by which hepatic stel-
late cells produce their own set of IGFs and IGF binding
proteins and, as shown here, specifically regulate affini-
ties and quantities of the respective receptor species. It
is proposed that the highly sensitive IGF and/or IGF
binding protein regulatory system might be involved in
the mechanism of hepatic stellate cell activation at the
onset of fibrogenesis. An intriguing observation made in
this study concerns the question by which mechanism
hepatic stellate cells are kept quiescent in normal liver
although they are exposed continually to mitogenic IGF-
I constitutively expressed and secreted by hepatocytes,
and possess a significant quantity of high affinity IGF-I
receptor, mainly in the untransformed status. As dis-
cussed previously, some antagonizing, inhibitory
mechanisms keeping hepatic stellate cells in a resting
condition have to be postulated (51). Potential inhibitory
mechanisms effective in the liver, which are of great
interest both clinically and theoretically, might concern
the extracellular matrix surrounding hepatic stellate
cells, the presence of soluble inhibitors, and "hepatocyte
contacting processes" between hepatic stellate cells and
hepatocytes (40). The latter structure might normally ex-
ert a kind of contact inhibition of hepatic stellate cells
in situ, which is released during damage of hepatocytes,
a prerequisite of the initiation of fibrogenesis in injured
liver (11, 12). Ongoing studies are concentrated on
these topics.
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